193 related articles for article (PubMed ID: 8147921)
1. Reduced joint counts in rheumatoid arthritis clinical trials. American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
Arthritis Rheum; 1994 Apr; 37(4):463-4. PubMed ID: 8147921
[No Abstract] [Full Text] [Related]
2. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
Boers M; Tugwell P; Felson DT; van Riel PL; Kirwan JR; Edmonds JP; Smolen JS; Khaltaev N; Muirden KD
J Rheumatol Suppl; 1994 Sep; 41():86-9. PubMed ID: 7799394
[TBL] [Abstract][Full Text] [Related]
3. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials.
Felson DT
J Rheumatol; 1993 Mar; 20(3):531-4. PubMed ID: 8478865
[TBL] [Abstract][Full Text] [Related]
4. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis.
Pincus T
Bull NYU Hosp Jt Dis; 2008; 66(3):216-23. PubMed ID: 18937635
[TBL] [Abstract][Full Text] [Related]
5. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
6. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
Pincus T; Amara I; Koch GG
Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
[TBL] [Abstract][Full Text] [Related]
7. The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials.
Boers M; Tugwell P
J Rheumatol; 1993 Mar; 20(3):568-74. PubMed ID: 8478876
[TBL] [Abstract][Full Text] [Related]
8. Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials.
Boers M; Kostense PJ
Arthritis Rheum; 2010 Dec; 62(12):3524-7. PubMed ID: 20722016
[No Abstract] [Full Text] [Related]
9. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores.
Yazici Y; Bergman M; Pincus T
J Rheumatol; 2008 Apr; 35(4):603-9. PubMed ID: 18322993
[TBL] [Abstract][Full Text] [Related]
10. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheumatoid Arthritis (MOI-RA).
Mäkinen H; Kautiainen H; Hannonen P; Sokka T
J Rheumatol; 2008 Aug; 35(8):1522-7. PubMed ID: 18484699
[TBL] [Abstract][Full Text] [Related]
11. Interpretation and power of a pooled index.
Goldsmith CH; Smythe HA; Helewa A
J Rheumatol; 1993 Mar; 20(3):575-8. PubMed ID: 8478877
[TBL] [Abstract][Full Text] [Related]
12. Assessing single joints in arthritis clinical trials.
Giles JT; Mease P; Boers M; Bresnihan B; Conaghan PG; Heald A; Maksymowych WP; Maillefert JF; Simon L; Tsuji W; Wakefield R; Woodworth T; Schumacher HR; Bingham CO
J Rheumatol; 2007 Mar; 34(3):641-7. PubMed ID: 17343312
[TBL] [Abstract][Full Text] [Related]
13. Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis?
van Riel PL; van Gestel AM
Arthritis Rheum; 2001 Jul; 44(7):1719-21. PubMed ID: 11465727
[No Abstract] [Full Text] [Related]
14. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data.
Yazici Y; Kautiainen H; Sokka T
J Rheumatol; 2007 Feb; 34(2):311-5. PubMed ID: 17304656
[TBL] [Abstract][Full Text] [Related]
15. Pooled outcome measures in arthritis: the pros and cons.
Roberts RS
J Rheumatol; 1993 Mar; 20(3):566-7. PubMed ID: 8478875
[TBL] [Abstract][Full Text] [Related]
16. Patient-driven outcomes in rheumatoid arthritis.
Wells GA
J Rheumatol Suppl; 2009 Jun; 82():33-8. PubMed ID: 19509328
[TBL] [Abstract][Full Text] [Related]
17. International consensus on which measures to use in rheumatoid arthritis clinical trials.
Boers M
Neth J Med; 1993 Aug; 43(1-2):55-8. PubMed ID: 7694164
[No Abstract] [Full Text] [Related]
18. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
Albert DA; Huang G; Dubrow G; Brensinger CM; Berlin JA; Williams HJ
J Rheumatol; 2004 May; 31(5):856-66. PubMed ID: 15124243
[TBL] [Abstract][Full Text] [Related]
19. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
Anderson JJ; Bolognese JA; Felson DT
Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
[TBL] [Abstract][Full Text] [Related]
20. MRI of rheumatoid arthritis image quantitation for the assessment of disease activity, progression and response to therapy.
Hodgson RJ; O'Connor P; Moots R
Rheumatology (Oxford); 2008 Jan; 47(1):13-21. PubMed ID: 18045811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
